New GABA Modulator Promising in Depression |
Journal Updates
eMediNexus Coverage from: 
New GABA Modulator Promising in Depression

1 Read Comments                

SAGE-217, a novel modulator of γ-aminobutyric acid–A (GABAA), reduced depressive symptoms in patients with major depression in a new study.

Investigators compared patients who had major depression and were treated with SAGE-217 to patients who received placebo for a 2-week period. They found that a larger percentage of patients in the SAGE-217 group demonstrated a response to the treatment or remission, compared to those in the placebo group. There were no serious or severe adverse events. The study was published online September 5 in the New England Journal of Medicine.


To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now